Physician profile
Sandra Mead
NPI 1619165727
$1,859.84
in general payments reported to CMS, 2019-2025
11 companies · $16.55 in 2025
The $16.55 reported for 2025 was less than what a typical Registered Nurse provider received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $441 · 2023: $494 · 2024: $644 · 2025: $16.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $467.20 | 2022-2024 | Airsupra |
| Amgen INC. | $441.38 | 2022-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $250.00 | 2021-2024 | Arexvy |
| Abbvie INC. | $150.58 | 2024-2025 | |
| Kyowa Kirin, INC. | $134.70 | 2021-2024 | |
| Novo Nordisk INC | $125.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $121.77 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $101.05 | 2023 | |
| Abbott Laboratories | $34.88 | 2023-2024 | Freestyle Libre 3 |
| Phadia US INC. | $18.24 | 2024 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $15.03 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Mead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.